These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
257 related items for PubMed ID: 35891592
1. Clinical characterisation of a multicentre nationwide cohort of patients with antisynthetase syndrome. Martins P, Dourado E, Melo AT, Samões B, Sousa M, Freitas R, Lourenço MH, Fernandes B, Costa E, Parente H, Martins F, Fonseca JE, Cordeiro I, Romão VC, Khmelinskii N, Campanilho-Marques R. ARP Rheumatol; 2022 Nov 01; 1(ARP Rheumatology, nº3 2022):190-196. PubMed ID: 35891592 [Abstract] [Full Text] [Related]
2. Clinical characteristics and prognostic analysis of idiopathic inflammatory myopathy with positive anti-aminoacyl-tRNA synthetase antibodies: A single center experience. Zhang D, Wang H, Zhou X, Yang J, Liu Y, Wang W, Jiang P, Fan B. Immun Inflamm Dis; 2023 Nov 01; 11(11):e1085. PubMed ID: 38018600 [Abstract] [Full Text] [Related]
3. A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA, Albayda J, Paik JJ, Johnson C, Silhan L, Christopher-Stine L, Mammen AL, Danoff SK. Rheumatology (Oxford); 2017 Jun 01; 56(6):999-1007. PubMed ID: 28339994 [Abstract] [Full Text] [Related]
4. Clinical Profiles and Prognosis of Patients with Distinct Antisynthetase Autoantibodies. Shi J, Li S, Yang H, Zhang Y, Peng Q, Lu X, Wang G. J Rheumatol; 2017 Jul 01; 44(7):1051-1057. PubMed ID: 28461650 [Abstract] [Full Text] [Related]
14. Novel endotypes of antisynthetase syndrome identified independent of anti-aminoacyl transfer RNA synthetase antibody specificity that improve prognostic stratification. Wu S, Xiao X, Zhang Y, Zhang X, Wang G, Peng Q. Ann Rheum Dis; 2024 May 15; 83(6):775-786. PubMed ID: 38395605 [Abstract] [Full Text] [Related]
15. Clinical characteristics of interstitial lung diseases positive to different anti-synthetase antibodies. Jiang M, Dong X, Zheng Y. Medicine (Baltimore); 2021 May 14; 100(19):e25816. PubMed ID: 34106621 [Abstract] [Full Text] [Related]
20. Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response. Bauhammer J, Blank N, Max R, Lorenz HM, Wagner U, Krause D, Fiehn C. J Rheumatol; 2016 Aug 01; 43(8):1566-74. PubMed ID: 27252419 [Abstract] [Full Text] [Related] Page: [Next] [New Search]